News

  • License

    Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension: the licenses.

  • Clinical Trial

    Together with our subsidiary RHEACELL we are now recruiting patients with the indication chronic venous ulcer (CVU) for the clinical trial in phase 1/2a. For more information click HERE.
  • ABCB5

    Review scientific facts regarding ABCB5 expression in normal tissue-specific stem cells HERE.
  • The Story of Stem Cells

    Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.
  • Research

    Always keep yourself up to date in our new category "Research Projects" about the realization of our current research projects and experience how ABCB5-positive stem cells open new opportunities in the case of medical need in the future.
  • Career

    Find our latest job offers HERE.
News
License

Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

Clinical Trial

Together with our subsidiary RHEACELL we are recruiting patients with the indication chronic venous ulcer (CVU) for the clinical trial in phase 1/2a. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.

Newsletter